ALLERGEN/INFLAMMATORY TESTING AND DIAGNOSIS

Abstract: The invention relates to the use of a secretor variant cell-line expressing the alpha moiety of human IgE binding protein to determine the allergic status of a given individual. Moreover, the cell-line is also used to provide an assay system for determining the allergenicity of substances and for subsequently providing therapeutic compositions which render said substances ineffective. In addition, the invention also relates to the use of said cell-line to determine the IgE independent irritancy of substances and compositions effective for attenuating the effects of said substances.

Description: Al lergen/Inflammatory testing and diagnosi s The invention relates to a method and test system for determining an individual s sensitivity to at least one pre-selected allergen/irritant and for determining the aUergenicity or inflammatory characteristics of chemicals; further, the invention also relates to a therapeutic treatment for attenuating antigen-inαuced or ιnflammatory τ ιnduced mediator response to allergenic or inflammatory stimulation, respectively. The response of an individual sensitive or responsive to a particular allergen or irritant is typically characterized by, amongst other things, an inflammatory response. This inflammatory response is produced as a result of the release of pharmacologically active mediators from mast cells and basophils. The activation of these cells in allergic responses such as asthma and hay fever is known to be mediated by the antibody IgE. It is known that there is a high-affinity receptor for IgE (FceR1 ) on the surface of mast cells and basophils, and further that the aggregation of IgE- occupied receptors by antigen is responsible for the release of allergic mediators from such cells. The FceR1 receptor is known to be made of at least three different SUD units, alpha, beta ana gamma. The alpha sub unit is known to bind IgE. Investigators have successfully transfected the human FceR1 alpha sub unit into a rat mast cell-line RBL-2H3 thus producing a rat mast cell-line which is capable of expressing the human FceR1 alpha. We have successfully transfected human FcerRI alpha sub unit into a rat mast ce:.-ιιne RBL-2H3 and the precise techπiαues which we used are αescnbec in detail in the following references: Conservation Of Signal Transduction Mechanisms Via The Human FceR1 Alpha After TransvecTion into A Rat Mast Cell-Line RBL-2H3, Gilfillan. A. M., Kado- Fonq. H. Wigqan. G. A., Hakimi. J.. Kent, U., and Kochan J. P., Journal of Immunology 149, 2445-2451 1992; Revisiting the Basophil Degranulation Test, Wilson. A. P. M., Moreira-Machado. D., Rhodes. N., Ahmad. T. B., Pullar. C. E., and Helm. B. A., Journal of Clinical Immunoassay 16, 91 -95 1993; ana Human IgE mediates stimulus secretion coupling in rat basophmc leukemia cells transfected with the alpha chain of the human high-affinity receptor, Wilson. A.. P. M., Pullar. C. E., Camp. A. M., and Helm. B. A., European Journal of Immunology 23, 240-244, 1993. The information and features described in these prior publications implicitly belong to the description of the invention contained in this application and thus to tne content of this application. It is of note that such information and features contribute to achieving the technical aim of the invention, that is to provide a method and test system for determining sensitivity to an allergen or irritant and therapeutic treatments for attenuating same, and as such are comprising the solution of the technical problem underlying the invention which is the subject of this application. It follows that protection may be sought for such features described in these prior publications. It has oeen found that this cell-line is a useful tool for understanding the fundamental steps involved in the above described response. However, we have used a high secretor variant of this cell-line to develop a method, and corresponding assay system, for determining the allergic/inflammatory status of an individual to a pre-selected allergen/irntaπt. Moreover, we have also used this cell-line for determining the potential allergenicity/irritancy of pre-selected chemicals. Further, the cell-line has been used to develop a therapeutic treatment for attenuating antigen- induceα or inflammatory mediator response to allergenic or irritant stimulation. Turπiπg :o the first methoα and corresponding assay system, it is known that inαividuals sensitive to a particular allergen have in their serum auergen soecmc IgE molecules, these are also known as sensitizing agents. This information has been used in the past to develop skin tests z for the DurDose of determining the allergen sensitivity of a given individual. However, these skin tests are potentially dangerous since they can nave a booster effect in an alreaαy sensitized individual and in some countries such skin tests are illegal. We have therefore used the afore described secretor variant to develop a 0 methoα which includes incubating the cell-line with serum from an individual to be tested and then challenging the cell-line with a pre¬ selected allergen. It follows that if an individual's ≤erum contains allergen specific IgE which corresponds to the allergen to be tested, the cell-line will respond in an 5 immuno-reactive way and release pharmacologically active mediators. The detection of these mediators is therefore a means of determining whether an immunogenic reaction has taken place. This in turn signifies the allergic status of the individual. According to a first aspect of the invention there is therefore provided a 0 method for determining the allergic status of an individual compπsiπg: 1 exposing a mast cell-line or basophil cell-line to a sensitizing agent; 2. challenging the cell-line with at least one allergen; and 3. determining the release of mast cell or basophil mediators in 5 response to said challenge. ln a preTerreα method of the invention the said sensitizing agent comprises numan serum and more preferably human serum from the said individual, or alternatively, said sensitizing agent comprises human IgE or a functional equivalent thereof. In a prererreo method of the invention the mast cell-line is an RBL-2H3 cell-line Dut in any case the cell-line is transfected with a moiety capable of binαing numan IgE with high-affinity. Alternatively the cell-line is a secretor variant and is of mast cell or basophil lineage and is transfected with a moiety capable of binding human IgE. Furthermore, ideally, the cell-line is first pre-incubated in a solution containing raαio active, or other, marker, preferably histamine or tntiated 5-hydroxytryptamιne (3H]-5HT (1 uCι/ml) or 1 c arachadonic acid ideally until eαumbrium has taken place, then the cells are washed to remove traces of extra cellular radio activity. The cells are sensitized and challenged with allergen. At the end of the reaction the cellular environment in which the cell-line is located, that is supernatant, is assayed for the presence of radio active marker such as histamine or tntiated 5-hydroxytryptamιne [3H]-5HT or 14C arachadonic acid, thus indicating the release of same from said cells. A commercially preferred method of the invention compπses the use of a spectropnotometπc or colourimetπc means for determining the release of mast cell mediators. For example, the release of cell mediators such as proteases is detected by including in the cellular environment, or supernatant, a chromogen that is acted upon by said proteases in such a way that a colour change is observed. However, it is within the scope of the invention to determine protease release by using any known proteolytic assay. Alternatively, it is within the scope of the invention to determine mast cell or basophil cell activation by measuring ionic fluctuations such as mobilization of intercellular calcium or membrane potential fluctuations. ln a furrer preferred method of the invention, cell mediator release is αetermineα DV the use of standard antibodv binding assays which soeαficai.v identify a pre-selected cell mediator. It will be unαerstood that the determination of a reaction can be undertaken by determining the release of any pre-selected mast cell mediator, ror example, one could assay for the presence of interleukins such as interleukin 3, 4, 5 6, and 8. According to a further feature of this aspect of the invention, there is provideα an assay system for determining the allergen sensitivity of an individual comprising- 1 an amount of mast cell-line or basophil cell-line; 2. an amount of test allergen; and 3. means necessary to determine the absence or presence of an immune response. In a preferred embodiment of the invention the cell-line is an RBL-2H3 cell-line Dut in any case the cell-line is transfected with the alpha-chain of the human high-affinity receptor for IgE. Alternatively, the cell-line is a secretor variant of a human mast cell-line or numan basophil cell-line expressing moieties which bind human IgE with high— affinity. Further, the preferred means comprise either an amount of radio active marker and ideally a radio active marker sucn as, but not limited to, tntiated 5-hydroxytryptamιne or 14c arachadonic acid. Ideally the means is a chromogen or alternatively a means of measuring proteolytic activity or alternatively an assay means We have also αeveloped the use of a mast cell or Dasophil cell-line to αetermine the potential aUergenicity of a given chemical. It is known that some chemicals can give rise to an inflammatory response wnich appears to be IgE independent. Such chemicals include bee and vespid venoms (the causative agents identified from tnese sources are oasic proteins like mellitin and mastopran, phospholipase A, cysteine and senne protease, a number of lectins, including viral haemagluttinins that interact with carbohydrate residues on the receptor and/or IgE, and sulfiting agents (food preservatives). Using the invention we have detarmined that the following chemicals elicit the release of mast cell mediators from our cell-lines and would therefore seem to give rise to an inflammatory response which is IgE independent. These cnemicals include bacterial phospholipase C (B cereus), house dust mite proteins, salicylates (aspirin based drugs), latex suspensions, extract from manufactured latex products (gloves, condoms) and spermicide. The mechanism by which these chemicals induce mast cell exocytosis in the absence of IgE has yet to be elucidated, however, the fact that this effect occurs means that a mast cell or basophil cell-line can be used to determine the potential aUergenicity of chemicals by exposing the cell-line to chemicals ana determining the absence or presence of a reaction by determining mast cell exocytosis or mediator release. According to a second aspect of the invention there is therefore provided a method for determining the potential irπtancy of a pre-seiected substance comprising: 1 . exposing a mast cell-line and/or basophil cell-line to a pre¬ selected amount of said substance; and 2. tnen determining the release of mast cell and/or basopnii cell- mediators in response to said exposure. In a preTerred method of the invention the mast cell-line is a secretor variant oτ a cell-line such as a RBL-2H3 cell-line which may or may not be transTected with a moiety capable of binding human IgE with high- affinity. In a preferred method of the invention and especially wnere the substance to be tested reacts with a cell bound immunoglobuiin of IgE isotype the mast cell-line or basophil cell-line is also exposed to an amount of IgE or a functional equivalent thereof. In this case, where the mast cell-line or basophil cell-line is incubated with IgE, it is preferable to use the transfected RBL-2H3 cell-line, or a human cell-line. Further, in a preferreα emoodiment, the mast cell-line is pre-incubated with radio active marker and ideally tntiated histamine or 5-hydroxytryptamιne or 14c aracnadonic acid, ideally uh ' til equilibrium has taken place, and then the cells are washed to move any extra cellular radio active or tntiated substances. The cells are then exposed to the said chemical and the cellular environment is then preferably assayed for the presence of radio active marker such as tntiated histamine thus indicating the release of same from said cells. In a yet further preferred embodiment of the invention the cell-line is exposed to a chromogen which changes colour as a result of the presence of a reaction. In a yet further preferred embodiment of the invention the release of cell mediators is determined using standard proteolytic assays or antibody assays as described aoove. Or, alternatively, by monitoring transmembrane or intracellular ion fluxes. We have further used the cell-line to identify therapeutic compositions for attenuating antigen-induced or irπtaπt-induceα mediator response to allergenic stimulations or irritants. We have found that many of the primary effects of ooth chemical- or irritant-induced mediator release from mast cell-lines ana basophil cell-lines and IgE mediated, antigen-inαuced mediator release from mast cell-lines and basophil cell-lines can be attenuated by selective substrates or inhibitors for mast cell and basophil derived proteolytic enzymes. Such substrates or inhibitors may inhibit triggering of target cells but will also inhibit the secondary activation which is probaoiy due to the release of mast cell and basophil proteases. We have also found that similarly, competing sugars, (which were identified on the basis of proteins that interact with carbohydrate residues on either IgE or cells expressing cellular receptors) such as N-acetyl-D-glucosamin, a-rπethyi-maπnoside, N-acetyl neuramiπic acid, b-D-galactose, a-L- fucose, and lactose can inhibit the triggering of mast cells and basophils oy interaction with lectins present in, for example, pollen or bacterial and viral aggiutiniπs. We have therefore successfully identified a number of substances which may be called antagonists and which may be responsible for inhibiting the activation of a mast cell-line or basophil cell-line. According to a yet further aspect of the invention there is therefore provided a therapeutic composition comprising a substance containing a C-terminal lysine or arginine residue for the treatment of an allergic reaction. According to a yet further aspect of the invention there is provided a therapeutic composition comprising a substrate or inhibitor, competitive or otherwise, of mast cell or basophil proteases for the treatment of an allergic reaction. According to a yet further aspect of the invention there is provided a further therapeutic composition comprising a competing sugar that interacts with carbohydrate residues on either IgE or cells expressing lectin binding moieties for the treatment of an allergenic reaction. ln a preferred embodiment the sugar comprises N-actetyl-D-giucosamin or a-meinyl-maπnoside or N-acetyl neuraminic acid or b-D-galactose or a-L-fucose or lactose or other biologically active derivatives. An emooαiment of the invention will now be described by way of example only. Figure 1 Histogram of the release of 5-hydroxytryptamιne (5HT) from transfected cell-lines. Clones were incubated for 24 hours at 37 degrees C with Dex, o-dinitroonenol (DNP)-specιfιc rat IgE or 4-hydroxy-3-πιtrophenacetyl caoroic acid (NΙP)-specιfιc human IgE (hlgE) in the presence of Dexametπasone (Dex) (10-8M) and [3H]-5HT. Cross-linking of receptor occupied IgE was effected with either DNP or NIP linked to human serum albumin (HSA) in the presence and absence of 5'(N-ethylcarboxyamido)- adenosine (NECA) (100 μM). [3H]-5HT was measured after a 15 minutes incubation period and release was corrected for background and expressed relative to the total tntiated [3H]-5HT incorporated. Figure 2 A comparison of the release of [3H]-5HT and β-hex-osaminidase. Transfected cells (H 2/2/C) were incubated with Dex (10-6M), NIP- specific hlgE (1 μg/mL) and, where appropriate, [3H]-5HT for 24 hours at 37 degrees C. The cells were washed and triggered with NIP-HSA in the presence of NECA (100 μM). The release of pre-loaded [3H]-5HT (•) and endogenous -hexosaminidase (O) were assessed. Each value is the mean of two tests; release was corrected for bacκαround. Figure 3 Triggeπng of RBL-2H3 (H 2/2/C) transfectants following sensitization with serum from a oee-venom-allergic individual. Cells were incubated with tne serum (1 :10), Dex (10-6M) and [3H]-5HT. After washing and pre- incubation the cells were challenged with a range of concentrations of puπfieα oee venom pnospholipase A2 (PLA2). The percentage release of [3H]-5HT (•) and -hexosammidase (O) were determined; data were corrected for background and normalized with respect to values obtained for triggeπng with hlgE-DNP (1 μg/mL) and NIP-HSA (100 ng/mL). Figure 4 Transfected RBL-2H3 clones were incubated for 24 hours with or without serum (1 :10 dilution) from a bee venom sensitive individual (EC) in the presence of 10-6M dexamethazone and [3H]-5-hydroxytryptamιne. After washing, cells were challenged with antigen in the presence of 100μM 5' (N-ethylcarboxyamιdo)-adenosιne (NECA). [3H]-5-Hydroxytryptamιne was measured after a 15 minutes incubation period, release was corrected for background and expressed relative to the total [3H]-5-hydroxytryptamιne incorporated. For experimental details see Wilson. A. P. M., Pullar. C. E., Camp. A. M.. and Helm. B. A., Human IgE Mediates Stimulus Secretion Coupling in Rat Basophilic Leukemia Cells Transfected with the Alpha Chain of the Human High-Affinity Receptor, European Journal of Immunology, 23:240-244, 1993, or alternatively, please see other references cited on Page 2 of this application. Tqfrle 1 Parameters for the binding of lodinated p 25-| ] rat and human IgE to parental and transfected clones. Clones were plated at 5 x 104 cells/well and incubated with Dex (10-6M) for 24 hours at 37 degrees C. Parental cell-lines (RBL-2H3 intermediate secretors (I) and high secretors (H)) were incubated in the absence (A) and presence (B) of the steroid. Cells were incubated with a range of concentrations of [125|] labelled rat or hlgE in the presence ana absence of a 50- 100-fold excess of unlabelled ligand (for experimental details see Wilson. A. P. M., Pullar. C. E., Camp. A. M., and Helm. B. A., Human IgE Mediates Stimulus Secretion Coupling in Rat Basophilic Leukemia Cells Transfected with the Alpha Chain of the Human High-Affinity Receptor, European Journal of Immunol'ogy, 23:240-244, 1993, or alternatively, please see other references cited on Page 2 of this application). Before counting, cells were washed and lysed, and the data were analyzed by the method of Scatchard. nb = non binder; N = number of determinations Table 2 Antigen-induced mast cell mediator release from RBL-2H3 ceils in the absence of sensitization with antigen-specific IgE. Parent RBL-2H3 cells or clones transfected with the α-chain of the human high— affinity receptor complex were plated out in 24-well plates at 2 x 105 cells/well as described previously in the citations referred to on Page 2 of this application. For the determination of antigen-induced mediator release, plates were incubated at 37 degrees C for 15 minutes, cooled on ice, the supernatant was removed, spun at 200 x g (1 minute) □efore ncuid scintillation counting to measure [3H]-5-hydroxytryptamιπe 5-HT) release The ImmunoTech histamine enzyme immunoassay was used to αuaπtifv histamine release, and hydrolvsis of toluene sulohonyl methyl ester was employed to monitor protease release (please see Wilson. A P. M., Pullar. C. E.. Camp. A. M., and Helm. B. A., Human IgE Mediates Stimulus Secretion Coupling in Rat Basophilic Leukemia Ceils Transfected with the Alpha Chain of the Human High-Affinity Receptor, European Journal of Immunology, 23:240-244, 1993, or alternatively, please see other references cited on Page 2 of this application). - 3-8% mediator release 8-15% mediator release — -f 15-25% mediator release' ++++ 25-45% mediator release ND Not Determined Example 1 A method and corresponding assay system for determining the allergenic status of a given individual. 2 x 105 cells of RBL-2H3 transfected with the α-chain of the human high- affinity receptor for IgE were placed in at least one test well and incubated in a total reaction volume of 0.4ml buffer A or 24 hours at 37 degrees C with tntiated 5HT (1 uCi/ml), in the presence of serum from an individual to be tested, a 2-100 fold dilution of human serum was used. (This serum may or may not contain antigen specific IgE corresponding to the allergen in the test method/kit depending upon the allergenic status of the individual.) Foliowinc incuoation, the cells were washed (2 x 1 ml) with buffer A (120mM NaC1. 5mM KC1 , 25mM PIPES, 1 mM CaCl 2, 0.04mM MgCl 2, 5.6mM giucose. 0.1 % BSA, pH7.4) and pre-incubated for a period of 10 minutes at 37 degrees C with buffer A (0.5ml) which was removed before cnallenge with buffer A (0.4ml) supplemented with the antigen in an amount of nanogram, microgram or milligram concentrations depending on the efficacy of the antigen source. For the determination of antigen induced [3H]-5HT release, the well was mcubateα at 37 degrees C for 15 minutes, cooled on ice, supernatant was then removed and spun at 2000g (1 minute) before liquid scintillation counting (2 minutes). The percentage release of [3H]-5HT was calculated by the methoα of Siraganian and Hook (Manual of Clinical Immunology of the Ameπcan Society for Microbiology Washington DC, 1980 Page 808). Histamine release was dem'onstrated employing the ImmunoTech histamine immunoassay kit. (We have also determined the release of proteases from this cell-line and this was analyzed by the method of Hummel [Homodified Spectrophotometπc Determination of Chymotrypsin, Trypsin & Thrombin, Canadian Journal of Biochem Physiol Volume 37, Page 1959].) As mentioned, the ability of high-secretor variant clones to support mediator release through receptor-bound human IgE was determined either oy pre-loading the cells with [3HJ-5HT or oy measuring the release of endogenous 3-hexosamιnιdase. Briefly cells were plated out and incubated for 24 hours at 37 degrees C, with [3HJ-5HT (if appropriate), Dex, o-dιnιtrophenol-(DNP-) specific rat IgE or 4p-hydroxy-3- πitropnenacetyl caproic acιd-(NIP-) specific hlgE. The cells were washed with buffer A, pre-incubated for 10 minutes at 37 degrees C with the same buffer and challenged, in fresh buffer, with either DNP-HSA (DNP conjugated to human serum albumin) 50 ng/mi or NIP-HSA 10 ng/ml in tne presence of the adenosme analogue 5' (N-ethyicarboxyamιdo)- adenosiπe (NECA) 100 μM. Properties of the transfected line Following electroportation, transfection frequencies of 30 x 10-6 and 1 .5 x 10-6 were obtained for RBL-2H3 intermediate secretors (I) and RBL-2H3 high secretors (H), respectively. On the basis of hFceRl α expression, three clones, namely I 5/3/C, H 2/2/C and H 7/1 /A, were selected for further studies. Table 1 shows the relative number of receptors, following induction with Dex, demonstrating rat IgE and human IgE binding; rat IgE binds to tne humanized receptor. but with a 10-fold lower affinttv than the natural ugand. As the interaction of hlgE with its receptor is an order of magnituαe higner than the interaction of rat IgE with its receptor, the net result is that rat IgE engages hFceRI σ with the same affinity as the rodent receptor. In addition to the data in Table 1 , the rates of association and dissociation of rat and hlgE with I 5/3/C and rat IgE with the parental line RBL-2H3 (I), and the K values calculated from these on/off rates were consistent with published data. A feature of this application is the ability of the transfected cell-line to support mediator release in response to cross-linking receptor- associated hlgE. Significant release required the presence of NECA (100 μM), at the cross-linking stage, in order to counteract the effect of Dex. This steroid decreases antigen-induced cell secretion but increases the responsiveness to NECA. It has been suggested that Dex down-regulates the expression of the G protein Gσz that may play a role in coupling the FceR1 complex to effector systems involved in mast cell exocytosis. Figure 1 shows the release of 5HT from transfected cell-lines following priming with either rat or human IgE and clearly demonstrates the effect of NECA. Simulation through hFceRI σ gave consistently higher release than when degranulation was effected through the native rodent receptor complex. Figure 2 shows a comparison between the release of -hexosamιnιdase and preioaαed [3H]-5HT from H 2/2/C following hlgE-mediated, antigen- induceα αegranulation. The two assay systems compare reasonably well, although the former consistently yields lower values (7-10%) than [ 3 H]- 5HT measurements. An example of the use of the transfected cell-line for the measurement of antigen-soecific IgE is shown in Figure 3, clone H 2/2/C was incubated with serum from a bee-venom-sensitive individual (EC) and challenged with bee venom PLA2 A typical bell-shaped dose response curve for the release of 3-hexosamιnιdase and [3H]-5HT was observed when the IgE sensitizeα cell-line was challenged with increasing concentrations of PLA2- Again the percentage release of β-hexosarπιnιdase was less than that observed for [3HJ-5HT These results thus illustrate that the cell-line we have developed can be used, as we alone have realized, for the provision of a method and an assay system which can detect the allergenic status of an individual. Example 2 A method and corresponding assay system for detecting the potential irntancy or aUergenicity of chemicals. 2 x 105 cells of the RBL-2H3 cell-line transfected with the α-chain of the human high— affinity receptor for IgE were placed in at least one incubator well and incubated in a total volume of 0.4ml of buffer A (120mM NaC1 , 5mM KC1. 25mM PIPES, 1 mM CaCl 2, 0.04mM MgCl 2, 5.6mM glucose, 0.1 % BSA, pH7 4) for 24 hours at 37 degrees C with [3H]-5HT (1 uCι/ml). (In this instance, in the presence of human serum and therefore in the presence of any antigen specific IgE.) Followinc incuoation, the cells were washed (2 x 1 ml) with buffer A ana pre-inc oated for a period of 10 minutes at 37 degrees C with buffer A ,0.5ml) .vnich was removed before challenge with buffer A (0.4ml) supplemented with the irritant or antigen. The amount of irritant or antigen was in tre range of naπograms, micrograms or milligrams depending on tne efficacv of the irritant source. For the αetermination of irritant or antigen induced [3H]-5HT release, the well was incubated at 37 degrees C for 15 minutes, cooled in ice, supernatant was then removed and spun at 2000g (1 minute) before liquid scintillation counting (2 minutes). The percentage release of [3H]-5HT was calculated by the method of -Siragaπian and Hook. Histamine release was demonstrated employing the ImmunoTech histamine immunoassay kit. (We have also determined the release of proteases from this cell-line and this was analysed by the method of Hummel) When the transfected cells were sensitized with the serum from a bee venom pnospholipase A2 sensitive individual (EC), mediator release could be demonstrated following challenge with purified bee venom phospholipase A2 (mellitin free). A typical bell-shaped dose response pattern was observed when the sensitized cells were challenged with increasing doses of antigen. Control experiments, where non-sensitized cells had been incubated with the same concentration of antigen in the absence of sensitizing serum also showed degranulation of mediators, but this time mediator release increased in response to antigen concentration (see Figure 4) , Employing this cell-line, we were able to demonstrate that even in the absence of IgE several well defined allergens, (which in susceptible individuals give rise to an IgE response following the initial encounter) such as bee and vespid proteins, phospholipases, proteases from house αust mites aπα fungal spores, lectins present in pollen and grain, latex- associated proαucts and spermicides, and aspirin based drugs can trigger the release of substantial levels of mediators of the allergic response from these ceπs (see Table 2). The above results indicate that, as we have realized, our cell-line can be used for determining the potential irπtancy or aUergenicity of a chemical or substance. Example 3 In the αevelooment of a therapeutic composition for attenuating antigen- induced mediator response to allergenic stimulation the following method was useo. 2 x 105 cells of the RBL-2H3 cell-line transfected with the α-chain of the human high-affinity receptor for IgE were placed in at least one incubation well in a total reaction volume of 0.4ml of buffer for 24 hours at 37 degrees C with [3H]-5HT (1 uCι/ml), in either the presence or absence of antigen specific IgE, that is either in the presence or absence of human serum (as above described) depending upon the nature of the allergic reaction to be attenuated. For example, where a composition was being tested or developed for its ability to attenuate an IgE mediated response such as asthma or hay fever, antigen specific IgE would be present, for example, in the form of human serum. Following incubation, cells were washed (2 x 1 ml) with buffer A (120mM NaC1 , 5mM KC1 , 25mM PIPES, 1 mM CaCl 2, 0.04mM MgCl 2, 5.6mM glucose, 0.1 % BSA, pH7.4) and pre-incubated for a further period of 10 minutes at 37 degrees C with buffer A (0.5ml) which was removed before challenge with buffer A (0.4ml) supplemented with a pre-selected antigen (in an amount as afore described) and the therapeutic composition or the antagonist. For the cetermination of antigen induced 3H]-5HT release, the well was incubated at 37 degrees C for 15 minutes, cooled on ice, supernatant was then removed and spun at 2000g (1 minute) before liquid scintillation counting :2 minutes). The percentage release of [3H]-5HT was calculated by the method of Siraganian and Hook. Histamine release was demonstrated employing the ImmunoTech histamine immunoassay kit. (We have also determined the release of proteases from this cell-line and this was analysed by the method of Hummel) In the instance where the therapeutic composition acted as an effective blocker of the antigen-induced allergic response, there was a significant reduction in [3H]-5HT release. Activated mast cells and basophils also secrete at least three proteases, the physiological function of which is unknown. These enzymes are seπne endoproteases with a trypsin-like specificity. We have recently shown that after secretion following an immunological or non-immunological stimulus, proteases released from the activated RBL cell-line can induce mediator secretion from cells of their kind. This secondary burst of the release of inflammatory mediators can be attenuated by the inclusion of protease inhibitors or substrates for seπne proteases like the synthetic substrate p-toluenesulphonyl-L-arginine methyl ester (TAME) or the human IgE-deπved pentapeptide (HEPP) in the medium bathing the cells. This observation provides a self-evident explanation for the observed therapeutic effect of administration of HEPP to patients suffering from eg allergic minitis, initially attributed to be due to competitive inhibition of the lgE/FceR1 interaction, but later held untenable. It will be understood that the therapeutic composition identified using the above method may be manufactured in any saleable form such as a pill, capsule, lozenge, tablets, medicine, infusion, ointment, nasal spray, inhalant or any other known means of manufacturing a medicament. it will be understood that althougn the examples have been oescπoed py -eference :o an immuno-radioactive method, it is within the scope of the ■ πvention to deploy a colourimetπc technique, or proteolytic assay, or .mmunoiogical assay, or antibody assay, or indeed any other standard tecnπioue of assay such as a measurement of membrane potential for αetermining the response of a mast cell-line or basophil cell-line to a given allergen or antagonist unoer the above specified conditions.

Claims: CLAIMS 1. A metnod for determinina the allergic status of an individual compnslma: 1. exposing a mast cell-line andior basophil cell-line to a sensitizing agent; 2. cnallenging the cell-line with at least one allergen; and 3. aetermining the release of mast ceil or basophil mediators In resoonse to said challenge. 2. A method according to Claim 1 wnerein the cell-line Is a secretor vanant of mast cell or basophil lineage and is transfected with a moiety capable of binding human IgE. 3. A method according to Claim 1 or 2 wherein said mast cellline is an RBL-2H3 cell-line which is transfected with the a-chain at least of the human high-affinity receptor for IgE. 4. A method according to Claim 1 wherein said sensitizing agent is human IgE or a functional equivalent. 5. A method according to any preceaing Claim wherein said cell-line Is pre-incubated In a solution containing a radio active marker. 6. A method according to Claim 5 wnerein said marker Is tritiated histamine. 7. A method according to Claim 5 wnerein said marker Is 14C arachadonic acid. A A method according to Claims 1-4 wherein sDectroor.otometnc means Is used to determine release of mediators. 9. A method according to Claims 1-4 wherein said release of mediators Is determined using an Immunoassay technique. 10. An assay system for determining the allergic status of an individuai compnsing: 1. an amount of mast cell-line and/or basophil cell-line; 2. an amount of test allergen; and 3. means necessary to determine the absence or presence of an Immune response. 11. An assay system according to Claim 10 wherein the cell-line is a secretor variant of a mast cell-line or a human basophil cell-line expressing moieties which bind human IgE. 12. An assay system according to Claims 10 or 11 wherein the cell-line Is an RBL-2H3 cell-line which is transfected with the alphachain at least of the human high-affinity receptor for IgE. 1 3. An assay system according to Claims 10-12 wherein there is further provided a pre-determined amount of radio active marker. 14. An assay system according to Claim 13 wherein said marker is tritiated histamine. 15. An assay system according to Claim 1 3 wherein said radio active marker is arachadonic acid. 16. An assay system according to Claims 10-12 wherein there s Droviaeo a cnromogen means for measuring release of mediators. 17. An assay system according to Claims 10-12 wherein there IS orovioea Immunoassay means for measurina release of mediators. 18. A method for determining the potential irritancy or allergenic;tv of a pre-selected substance comprising: 1. exposing a mast cell-line and/or basophil cell-line to said substance: and 2. then determining the release of mast cell andior basophil cell mediators in response to said exposure. 19. A method according to Claim 18 wherein said cell-line is a high-secretor variant. 20. A method according to Claim 18 or 19 wherein the cell-line compnses a moiety capable of binding human IgE. 21. A method according to Claim 19 or 20 wherein the cell-line Is a secretor vanant of RBL-2H3. 22. A method according to Claims 18-21 wherein said cell-line is pre-incubated with human IgE corresponding to the substance to be tested. 23. A method according to Claims 18-22 wherein said cell-line Is pre-incubated with a marker. 24. A method according to Claim 23 wherein the marker is tritiated 5-hydroxytryptamine or histamine. 25. A method according to Claim 23 wnerein the marKer Is 14C arachaaonic acid. 26. A method according to Claims 18-28 wherein the method compnses exposing said cell-line to a chromogen which changes colour as a resuit of the presence of an immunogenic reaction. 27. A method according to Claims 18-22 wherein the method compnses exposing said cell-line to an Immunoassay means for measuring release of mediators. 28. A therapeutic composition compnsing a substance containing C-terminal lysine or arginine residues for the treatment of an allergic reaction. 29. A therapeutic composition comprising a substrate or inhibitor of a mast cell or basophil protease for the treatment of an allergic reaction. 30. A therapeutic composition according to Claim 29 wherein said protease is a serine protease. 31. A therapeutic composition according to Claim 29 wherein said substrate Is p-toluenesulphonyl-L-arginine methyl ester (TAME). 32. A therapeutic composition according to Claim 29 wherein the inhibitor Is a human lgE-derived pentapeptide (HEPP). 33. A therapeutic composition comprising a competing sugar that interacts with carbohydrate residues on either lgE or cells expressing lectin binding moieties for the treatment of allergenic reaction. 34. A therapeutic composition accoraing to Claim 33 wherein said sugar compnses n-acetyl-D-glucosamin. 35. A therapeutic composition according to Claim 33 wnerein said sugar comprises a-methyl-mannoside. 36. A therapeutic composition according to Claim 33 wherein said competing sugar compnses N-acetyl neuraminic acid. 37. A therapeutic composition according to Claim 33 wherein said competing sugar comprises b-D-galactose. 38. A therapeutic composition according to Claim 33 wherein said competing sugar comprises a-L-fucose. 39. A therapeutic composition according to Claim 33 wherein said competing sugar compnses lactose.

Inventors: CAMP ANDREW, HELM BIRGIT ANNA, MOREIRA-MACHADO DENISE, PULLAR CHRISTINE ELAINE, WILSON ANNE PENELOPE MARGARET, CAMP, ANDREW, HELM, BIRGIT, ANNA, MOREIRA-MACHADO, DENISE, PULLAR, CHRISTINE, ELAINE, WILSON, ANNE, PENELOPE, MARGARET
Applicants: CAMP ANDREW, EURO DPC LTD, HELM BIRGIT ANNA, MOREIRA MACHADO DENISE, PULLAR CHRISTINE ELAINE, WILSON ANNE PENELOPE MARGARET, CAMP, ANDREW, EURO/DPC LIMITED, HELM, BIRGIT, ANNA, MOREIRA-MACHADO, DENISE, PULLAR, CHRISTINE, ELAINE, WILSON, ANNE, PENELOPE, MARGARET
Application year: 1993
Main classification: G01N33
IPC codes: A61K31, A61K38, C12N5, G01N33